Print

Purpose

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. - In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. - In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Conditions

Eligibility

Eligible Ages
Over 16 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation - Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation - For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma - For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma, - For Substudy B and C, measurable disease by RECIST version 1.1 - For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II/III alteration in tumor tissue and/or blood - For Substudy C, evidence of a BRAF founder alteration (non-V600 Class II/III BRAF alteration)

Exclusion Criteria

  • Brain metastasis larger than 4 cm - History or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Monotherapy Dose Escalation (Phase 1a) 		Participants will receive PF-07799544
  • Drug: PF-07799544
    Tablet
    Other names:
    • ARRY-134
  • Drug: encorafenib
    Capsule
    Other names:
    • BRAFTOVI
Experimental
Phase 1b Substudy B Combination Dose Escalation 		Participants will receive PF-07799544 and PF-07799933
  • Drug: PF-07799544
    Tablet
    Other names:
    • ARRY-134
  • Drug: PF-07799933
    Tablet
    Other names:
    • ARRY-440
Experimental
Phase 1b Substudy B Combination Dose Expansion 		Participants will receive PF-07799544 and PF-07799933
  • Drug: PF-07799544
    Tablet
    Other names:
    • ARRY-134
  • Drug: PF-07799933
    Tablet
    Other names:
    • ARRY-440
Experimental
Phase 1b Substudy C Combination Dose Expansion 		Participants will receive PF-07799544 and PF-07799933
  • Drug: PF-07799544
    Tablet
    Other names:
    • ARRY-134
  • Drug: PF-07799933
    Tablet
    Other names:
    • ARRY-440

Recruiting Locations

Brigham and Women's Hospital
Boston 4930956, Massachusetts 6254926 02115

More Details

Status
Recruiting
Sponsor
Pfizer

Study Contact

Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.